Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542371 | 1.00 | KDM4E (0.41) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL19284772 | 0.94 | KDM4E (0.40) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL19284774 | 0.94 | KDM4E (0.40) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL26194437 | 0.92 | LMNA (0.41) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL26314559 | 0.90 | ALDH1A1 (0.40) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL26314564 | 0.89 | KMT2A (0.42) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL29436357 | 0.88 | KDM4E (0.38) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17558480 | 0.88 | KDM4E (0.38) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17558482 | 0.88 | KDM4E (0.38) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL18468872 | 0.87 | KDM4E (0.37) | KDM4EKMT2ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552808-B2 | Diol desymmetrization by nucleophilic aromatic substitution | AMGEN INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033486-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | KDM4E 2252/4885KMT2A 1837/4885SMN1; SMN2 2311/4885 |
| US-12552808-B2 | Diol desymmetrization by nucleophilic aromatic substitution | MCL1, BAK1, BCL2 | KDM4E 3370/4885KMT2A 2283/4885SMN1; SMN2 158/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | KDM4E 2252/4885KMT2A 1837/4885SMN1; SMN2 2311/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM4E 1959/4885KMT2A 1766/4885SMN1; SMN2 1807/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | KDM4E 1959/4885KMT2A 1766/4885SMN1; SMN2 1807/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | KDM4E 1125/4885KMT2A 793/4885SMN1; SMN2 3223/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | KDM4E 1959/4885KMT2A 1766/4885SMN1; SMN2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.